Clinical Trials Logo

Other Cancer clinical trials

View clinical trials related to Other Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06397651 Recruiting - Breast Cancer Clinical Trials

A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live 1:1 Exercise Coaching and Personalised Digital Application on Cancer Survivors' Cost of Care

Start date: May 12, 2024
Phase: N/A
Study type: Interventional

A Decentralized, Double-blinded, Randomized, 18 month, Parallel-group, Superiority Study to evaluate the impact of Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application on Cancer Survivors' Cost of Care

NCT ID: NCT06103669 Recruiting - Breast Cancer Clinical Trials

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

VALOROUS
Start date: October 5, 2023
Phase: N/A
Study type: Interventional

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

NCT ID: NCT04585750 Recruiting - Breast Cancer Clinical Trials

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Start date: October 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.

NCT ID: NCT04340024 Recruiting - Prostate Cancer Clinical Trials

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Start date: September 30, 2015
Phase:
Study type: Observational

Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.

NCT ID: NCT03517332 Recruiting - Breast Cancer Clinical Trials

Circulating Tumor DNA Exposure in Peripheral Blood

Start date: January 1, 2015
Phase:
Study type: Observational

This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

NCT ID: NCT03160274 Recruiting - Pheochromocytoma Clinical Trials

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Start date: October 19, 2005
Phase:
Study type: Observational [Patient Registry]

Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.